Repository logo
 
Publication

Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide study

2022Journal article Open access
Simple item page
dc.contributor.authorMachado, Ana Rita
dc.contributor.authorBarreira, Sofia
dc.contributor.authorBandeira, Matilde
dc.contributor.authorVeldhoen, Marc
dc.contributor.authorGomes, Andreia
dc.contributor.authorSerrano, Marta
dc.contributor.authorDuarte, Catarina
dc.contributor.authorRato, Maria
dc.contributor.authorMiguel Fernandes, Bruno
dc.contributor.authorGarcia, Salomé
dc.contributor.authorPinheiro, Filipe
dc.contributor.authorBernardes, Miguel
dc.contributor.authorMadeira, Nathalie
dc.contributor.authorMiguel, Cláudia
dc.contributor.authorTorres, Rita
dc.contributor.authorBento Silva, Ana
dc.contributor.authorPestana, Jorge
dc.contributor.authorAlmeida, Diogo
dc.contributor.authorMazeda, Carolina
dc.contributor.authorCunha Santos, Filipe
dc.contributor.authorPinto, Patrícia
dc.contributor.authorSousa, Marlene
dc.contributor.authorParente, Hugo
dc.contributor.authorSequeira, Graça
dc.contributor.authorSantos, Maria José
dc.contributor.authorFonseca, João Eurico
dc.contributor.authorRomão, Vasco C.
dc.date.accessioned2023-06-07T14:43:51Z
dc.date.available2023-06-07T14:43:51Z
dc.date.issued2022
dc.descriptionCopyright © 2022 Cruz-Machado, Barreira, Bandeira, Veldhoen, Gomes, Serrano, Duarte, Rato, Miguel Fernandes, Garcia, Pinheiro, Bernardes, Madeira, Miguel, Torres, Bento Silva, Pestana, Almeida, Mazeda, Cunha Santos, Pinto, Sousa, Parente, Sequeira, Santos, Fonseca and Romão. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.pt_PT
dc.description.abstractObjective: To identify risk factors for SARS-CoV-2 infection and for severe/critical COVID-19, and to assess the humoral response after COVID-19 in these patients. Methods: Nationwide study of adult patients with inflammatory RMDs prospectively followed in the Rheumatic Diseases Portuguese Register-Reuma.pt-during the first 6 months of the pandemic. We compared patients with COVID-19 with those who did not develop the disease and patients with mild/moderate disease with those exhibiting severe/critical COVID-19. IgG antibodies against SARS-CoV-2 were measured ≥3 months after infection and results were compared with matched controls. Results: 162 cases of COVID-19 were registered in a total of 6,363 appointments. Patients treated with TNF inhibitors (TNFi; OR = 0.160, 95% CI 0.099-0.260, P < 0.001) and tocilizumab (OR 0.147, 95% CI 0.053-0.408, P < 0.001) had reduced odds of infection. Further, TNFi tended to be protective of severe and critical disease. Older age, major comorbidities, and rituximab were associated with an increased risk of infection and worse prognosis. Most patients with inflammatory RMDs (86.2%) developed a robust antibody response. Seroconversion was associated with symptomatic disease (OR 13.46, 95% CI 2.21-81.85, P = 0.005) and tended to be blunted by TNFi (OR 0.17, 95% CI 0.03-1.05; P = 0.057). Conclusions: TNFi and tocilizumab reduced the risk of infection by SARS-CoV-2. Treatment with TNFi also tended to reduce rates of severe disease and seroconversion. Older age, general comorbidities and rituximab were associated with increased risk for infection and worse prognosis, in line with previous reports. Most patients with RMDs developed a proper antibody response after COVID-19, particularly if they had symptomatic disease.pt_PT
dc.description.sponsorshipWe acknowledge the generous sharing of the expression constructs by Dr. Florian Krammer, Icahn School of Medicine at Mount Sinai, New York, USA [Development of SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C] and the protein production by Drs. Paula Alves and Rute Castro at Instituto de Biologia Experimental e Tecnológica (iBET) Oeiras, Portugal as part of the Serology COVID consortium.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFront Med (Lausanne). 2022 Jun 13;9:901817pt_PT
dc.identifier.doi10.3389/fmed.2022.901817pt_PT
dc.identifier.eissn2296-858X
dc.identifier.urihttp://hdl.handle.net/10451/58080
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFrontierspt_PT
dc.relation.publisherversionhttps://www.frontiersin.org/journals/medicinept_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCOVID-19pt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectAntibody responsept_PT
dc.subjectInflammatory rheumatic diseasespt_PT
dc.subjectSeroconversionpt_PT
dc.titleRisk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide studypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleFrontiers in Medicinept_PT
oaire.citation.volume9pt_PT
person.familyNameMachado
person.familyNameBarreira
person.familyNameBandeira
person.familyNameVeldhoen
person.familyNamedos Santos Gomes
person.familyNameFonseca
person.familyNameC Romão
person.givenNameAna Rita
person.givenNameSofia
person.givenNameMatilde
person.givenNameMarc
person.givenNameAndreia Filipa
person.givenNameJoão
person.givenNameVasco
person.identifier426629
person.identifierhttps://scholar.google.pt/citations?hl=en&user=7vG1jLIAAAAJ
person.identifier490119
person.identifier.ciencia-id2417-2F03-44CD
person.identifier.ciencia-idEF18-0C2D-4AB9
person.identifier.ciencia-id6413-A3A0-C7AD
person.identifier.ciencia-id1D1E-DE66-DB38
person.identifier.ciencia-idF310-B85D-57C7
person.identifier.ciencia-id771D-0A5C-626B
person.identifier.orcid0000-0003-0600-876X
person.identifier.orcid0000-0002-6807-559X
person.identifier.orcid0000-0001-8312-4532
person.identifier.orcid0000-0002-1478-9562
person.identifier.orcid0000-0003-2605-2565
person.identifier.orcid0000-0003-1432-3671
person.identifier.orcid0000-0002-5603-9436
person.identifier.ridO-8224-2014
person.identifier.scopus-author-id8323789000
person.identifier.scopus-author-id7101983519
person.identifier.scopus-author-id55989452300
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication47fa1e23-6318-4e58-a2b8-addce384ea94
relation.isAuthorOfPublication5f8b0c03-a0d8-4ac1-89e4-58164037ce57
relation.isAuthorOfPublication76e2bd61-5bd2-41af-8039-5423c979d0d7
relation.isAuthorOfPublicationb6ddef66-b6bb-4ce5-b68a-e4b211aa2411
relation.isAuthorOfPublicationed116f9d-03a0-4fcc-ab15-5aa484143268
relation.isAuthorOfPublication1772dc12-7c55-4c76-ae2d-c23270172480
relation.isAuthorOfPublicatione7e94139-add7-4a3b-b138-fb1d1a656b0e
relation.isAuthorOfPublication.latestForDiscovery1772dc12-7c55-4c76-ae2d-c23270172480

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Factors_severe.pdf
Size:
818.13 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.2 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

IMM - Artigos em Revistas Internacionais
FM-CUR-Artigos em Revistas Internacionais